The expression of transient receptor potential canonical 6 (TRPC6) in central nervous system (CNS) is important for neuronal functions and certain neural disorders. However, the regulatory mechanism of TRPC6 expression in neurons is still obscure. In this study, we show that TRPC6 expression in the primary cultured cortical neurons is bidirectionally regulated by glutamate. Activation of NR2A-containing NMDARs induces TRPC6 transcription through a calcineurin-dependent pathway. In contrast, activation of NR2B-containing NMDARs causes TRPC6 degradation through calpain. Thus, TRPC6 expression in neurons is regulated by glutamate in a bidirectional manner that is dependent on NR2A and NR2B.
The transient receptor potential canonical (TRPC) channels are Ca 2+ -permeable non-selective cation channels with diverse tissue distributions and physiological functions (Montell et al. 2002) . Its family has seven members, which can be divided into four subgroups based on their sequence similarity: TRPC1,TRPC2, TRPC3/6/7, and TRPC4/5 (Harteneck et al. 2000; Nilius and Owsianik 2011) . These subunits can form functional channels with homo-or heterotetramers which are located in almost all the regions of central nervous system (CNS) (Riccio et al. 2002; Clapham 2003; Vazquez et al. 2004) . Among these subunits, TRPC6 is notable for its wide variety of functions in CNS. Activating TRPC6 channels protects retinal ganglia cells in the retinal ischemia/reperfusion model . TRPC6 is also important for neuronal survival (Jia et al. 2007) , growth cone guidance (Li et al. 2005 ) and synaptogenesis in neural development .
However, dysregulation of TRPC6 expression is related to several neural disorders, including stroke (Du et al. 2010; Lin et al. 2013a,b) , epilepsy (Zeng et al. 2015 ) and Alzheimer's disease (AD) (Wang et al. 2015) . Therefore, maintaining an appropriate level of TRPC6 expression is important for neuronal functions. Nevertheless, how TRPC6 expression in the neurons is controlled remains unclear. It has been reported that TRPC6 expression can be up-regulated by platelet-derived growth factor through the c-Jun/STAT3 pathway in pulmonary vascular smooth muscle cells (Yu et al. 2003) . TRPC6 up-regulation is also observed in myocytes and podocytes through activating the calcineurin/ nuclear factor of activated T-cells (NFAT) pathway (Kuwahara et al. 2006; Koitabashi et al. 2010; Nijenhuis et al. 2011; Xie et al. 2012) . Further studies show that sustained activation of NMDARs can induce TRPC6 expression in podocytes (Kim et al. 2012 ). Previous reports demonstrate that blocking NR2A-containing NMDARs enhances neuronal death induced by ischemic stroke, while blocking NR2B-containing NMDARs attenuates ischemic cell death (Liu et al. 2007; Chen et al. 2008) . TRPC6 proteins are degraded by calpain during cerebral ischemia and inhibition of TRPC6 degradation prevents the ischemic neuronal damage (Du et al. 2010; Lin et al. 2013a,b; Yao et al. 2013) . In this context, it is speculative that TRPC6 expression can be differentially regulated by NR2A-and NR2B-containing NMDARs in the neurons.
In this study, we report that TRPC6 expression in neurons is regulated by NMDARs in a bidirectional manner. Activation of NR2A-containing NMDARs induces TRPC6 transcription, while activation of NR2B-containing NMDARs mediates TRPC6 protein degradation.
Materials and methods

Primary cell culture and drug treatment
The animals used in this study were approved by the Institute of Neuroscience, Chinese Academy of Science (Institutional approval number: 005). All the rats were anesthetized and treated following animal welfare guidelines of the Institute of Neuroscience, Chinese Academy of Science and in compliance with the ARRIVE guidelines. Primary cortical neurons were isolated and cultured as previously described with a little modification (Brewer et al. 1993) . Briefly, the neurons were obtained by dissociating the cortex from embryonic day 18 Sprague-Dawley (SD) rat (SLAK Laboratory Animal, Shanghai, China, RRID:RGD_12910483) brains and then seeded onto six-well plate or glass bottom dish coated with 50 lg/ mL poly-D-lysine (Sigma-Aldrich, Saint Louis, MO, USA). Cells were cultured at a density of 5 9 10 5 per well in six-well plates for western blots, mRNA extraction and PI staining, at a density of 1 9 10 5 per well in 35 mm dishes with 20 mm glass bottom well for Ca 2+ imaging. All cells were cultured in neurobasal supplemented with B-27 and 0.5 mM glutamax (Invitrogen, Carlsbad, CA, USA) for 10 days before use. Primary astrocytes were obtained from post-natal 0-1 day SD rat brains. After washing twice with phosphate-buffered saline, the brain tissue was digested with 0.05% trypsin. Then the digested brain tissues were triturated and passed over a 70 lm filter. Filtered cells were collected by centrifugation, suspended in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and cultured in cell culture flasks for 7-9 days. Astrocytes were then purified by shaking at 220 r/min overnight, and passed onto six-well plates in F12 medium with N2 supplement and basic fibroblast growth factor for 3 days. Then, the astrocytes were used for the experiments.
In the drug treatment experiments, calpeptin (Sigma-Aldrich), MK801 (Abcam, Cambridge, MA, USA), TCN201 (Torcris, UK), Ifenprodil (Sigma-Aldrich) and Cyclosporin A (CsA) (Selleck, Houston, TX, USA) were all administrated 15 min before glutamate treatment.
Transfection
The cultured neurons were transfected with siRNAs using Micropolytrasfecter TM Cell Reagent (Micropoly, China) according to its protocol. Briefly, the siRNAs (Genepharma, Shanghai, China) were dissolved in diethyl pyrocarbonate (DEPC) water at a concentration of 20 lM. Then, the siRNAs were mixed with transfection reagent followed by incubation for 10 min. The mixtures were applied into the cultures and the neurons were harvested 48 h later for the following experiments. 
Western blot
Total proteins were extracted from cultured cells using sodium dodecyl sulfate (SDS) lysis buffer (2% SDS, 10% glycerol, 0.1 mM dithiothreitol, and 0.2 M Tris-HCl, pH6.8). Then, the extracts were electrophoresed on SDS/PAGE and transferred to polyvinyldifluoridine membranes. The membranes were incubated with the indicated primary antibodies at 4°C overnight followed by incubation with the horse radish peroxidase-conjugated anti-rabbit or anti-mouse secondary antibodies at 20°C-30°C for 2 h. The protein bands were detected by the enhanced chemiluminescence detection system (Amersham Biosciences, Piscataway, NJ, USA). The density of the bands was determined by Image Quant Software (Amersham Biosciences, Piscataway, NJ, USA). Anti-TRPC6 antibody was purchased from SAB (SAB, #21403, USA, RRID: AB_1263792) and anti-TRPC3 antibody was generated in house (Feng et al. 2013) . Anti-spectrin antibody was from Millipore (Millipore Corporation, Bedford, MA, USA, MAB1622, GER, RRID: AB_94295), anti-NR2A antibody from R&D (R&D, PPS012, USA, RRID: AB_2112297), anti-NR2B antibody from Millipore (Millipore, 06-600, GER, RRID: AB_310193), the secondary antibodies from GE Healthcare (Amersham Biosciences, Piscataway, NJ, USA).
Ca
2+ imaging
The analysis of [Ca 2+ ] i was done as described previously (Zhu et al. 1996) . Briefly, the cortical neurons loaded with Fura-2 AM (2 lM) in the HEPES-buffered saline [HBSS: (in mM) 120 NaCl, 5. Quantification was calculated using the comparative Ct method (DDCt method) as suggested by the manufacturer (Applied Biosystems, Carlsbad, CA, USA). The cycle number at which the reaction crossed a threshold (Ct) was determined for the endogenous control (actin) and target (TRPC6). The relative amount of TRPC6, normalized to the endogenous control and relative to a common reference sample was calculated by the formula 2
ÀDDCt . The reaction for actin and TRPC6 was carried out in triplicate for each sample. The PCR products were sequenced to confirm the identity of the interest targets.
Statistics
Data are means AE SEM. We used t-tests for comparison between two groups. One-way analysis of variance (ANOVA) with StudentNewman-Keuls analysis was used for multiple group comparison, all the analysis was performed using SigmaStat (Systat, San Rafael, CA, USA). p < 0.05 were considered statistically significant. No blinding or randomization was performed in the study.
Results
TRPC6 expression in cultured cortical neurons is increased by glutamate
We initially examined whether TRPC6 expression could be regulated by glutamate in cultured cortical neurons. We found that TRPC6 mRNA level was greatly increased by glutamate in a manner that is depending on glutamate doses ( Fig. 1a ; n = 5, *p < 0.05; **p < 0.01; ***p < 0.001 vs. 0 lM). It reached the peak level at 50 lM glutamate (Fig. 1a) . In contrast, the mRNA level of TRPC3, known as a homologous subunit of TRPC6 (Harteneck et al. 2000) , was not changed after glutamate treatment ( Fig. 1a ; n = 4). Then, the time points were optimized under 50 lM glutamate treatment, we found that TRPC6 mRNA level showed a continuous elevation from 3 to 5 h after glutamate stimulation ( Fig. 1b ; n = 4, *p < 0.05; **p < 0.01 vs. 0 h). Additionally, treatment of the neurons with glutamate for 5 min also greatly increased TRPC6 expression (Fig. S1a) . Similarly, the protein level of TRPC6 was increased after glutamate treatment in the dose-dependent manner ( Fig. 1c ; n = 3, *p < 0.05; **p < 0.01 vs. 0 lM). In contrast, no change was observed about TRPC3 protein level ( Fig. 1c ; n = 3). Further, in the time-course experiments we found that TRPC6 protein level reached to the peak level 4 h after glutamate treatment and was followed by a downward trend (Fig. 1d ). The mRNA (n = 4) and protein (n = 3) levels of TRPC3 were not changed after glutamate administration ( Fig. 1b and d) . Thus, 50 lM glutamate treatment for 4 h, a condition without obvious effects on neuronal survival ( Fig. S2a and b ; n = 7), was used in the following experiments unless stated. Moreover, addition of 50 lM glutamate to the pure cultured astrocytes for 5 h did not change the mRNA ( Fig. 1e ; n = 5) and protein ( Fig. 1f ; n = 4) levels of TRPC6. Together, these results suggest that both mRNA and protein levels of TRPC6 in the cultured cortical neurons are specifically enhanced by glutamate.
NMDARs mediate both TRPC6 transcription and degradation
In the above time-course experiments although TRPC6 mRNA level was continuously elevated after glutamate treatment, its protein level showed a downward trend after 4 h of the stimulation (Fig. 1d ). These results indicated that TRPC6 expression might be regulated in a manner that is bidirectionally controlled during the process of glutamate treatment. It has been reported that calpain is activated through NMDA receptors, leading to TRPC6 degradation during cerebral ischemia (Du et al. 2010; Lin et al. 2013b ). Therefore, we next examined whether TRPC6 was degraded when the neurons were treated with glutamate. As shown in Fig. 2a , TRPC6 protein level was increased after glutamate treatment and a cleaved form of spectrin (spectrin break-down production 150/145 band, SBDP-150/145), commonly used as the indicator to reflect proteolytic activity of calpain (Sanderson et al. 1996) , was also found with the time of incubation. When the neurons were pre-incubated with calpeptin, known as an inhibitor of calpain, glutamate-induced TRPC6 enhancement at protein level was further augmented (Fig. 2b, c ; n = 3, *p < 0.05; **p < 0.01 vs. glutamate treatment). However, calpeptin treatment did not influence the change in TRPC6 mRNA levels ( Fig. 2d ; n = 4). These results suggest that activation of calpain attenuates TRPC6 increase at protein level, but does not affect TRPC6 increase at transcriptional level although TRPC6 at protein and mRNA levels are all induced by glutamate. Since activation of NMDARs is coupled with the increase in calpain activity (Hewitt et al. 1998) , we examined the effects of MK801, a specific inhibitor of NMDARs, on TRPC6 protein and mRNA expressions after glutamate administration. Treatment of the neurons with MK801 abolished the production of SBDP-150/145 induced by glutamate ( Fig. 3a ; n = 3), suggesting that MK801 inhibited calpain activation induced by glutamate. However, different from the treatment with calpeptin administration of MK801 did not increase TRPC6 protein levels although calpain activity was greatly suppressed. Even more, TRPC6 protein up-regulation induced by glutamate was also suppressed ( Fig. 3a, b ; n = 3, *p < 0.05 vs. control or glutamate treatment). These results are consistent with an explanation that in addition to inhibition of calpain activation MK801 also inhibits TRPC6 expression in a manner that is independent of calpain. Then, we examined the effects of MK801 on TRPC6 mRNA levels. We found that the enhancement of TRPC6 mRNA level induced by glutamate was also abolished when the neurons were incubated in the presence of MK801 ( Fig. 3c ; n = 4, **p < 0.01 vs. control or glutamate treatment). Collectively, these results thus point to an explanation that TRPC6 expression is regulated in a bidirectional manner that is mediated by NMDARs. On the one hand, TRPC6 is up-regulated by NMDARs at transcriptional level. On the other hand, the TRPC6 protein is degraded through calpain activation also resulted from stimulation of NMDARs.
NR2B-containing NMDARs mediate TRPC6 degradation through activating calpain
The NR2A and NR2B are the major components of NR2 subunits in adult brains. Further, it has been reported that NR2A-and NR2B-containing NMDARs exert opposing roles in gene expression (Hardingham et al. 2002) . Therefore, we next tested the possible roles of NR2A-and NR2B-containing NMDARs in TRPC6 expression. As shown in Fig. 4a , the production of SBDP-150/145 was greatly inhibited by Ifenprodil (n = 4), an agent known as a specific antagonist for NR2B-containing NMDARs (Hess et al. 1996) . Therefore, activation of calpain was mediated by NR2B-containing NMDARs. Moreover, TRPC6 protein level was further augmented when the neurons were incubated with glutamate in the presence of ifenprodil ( Fig. 4a and b ; n = 4, *p < 0.05 vs. control or vehicle) without effects on neuronal survival (Fig. S2a, b ; n = 7). In contrast, the increase in TRPC6 mRNA levels induced by glutamate was not changed when the neurons were incubated in the presence of ifenprodil ( Fig. 4c ; n = 4, *p < 0.05 vs. control).
To confirm the roles of NR2B-containg NMDARs in TRPC6 expression, we examined the effects of downregulation of NR2B by siRNAs on TRPC6 expression. Three siRNAs targeting NR2B were examined and two with a clear down-regulation of NR2B were used in the following study ( Fig. S3b ; n = 3). TRPC6 protein levels induced by glutamate was further enhanced when the neurons were transfected with the two siRNAs against NR2B (Fig. 4d, e ; n = 4, *p < 0.05; ***p < 0.001; n.s. means no statistical difference). In contrast, TRPC6 mRNA levels were not changed when the neurons were transfected with the two siRNAs against NR2B ( Fig. 4f ; n = 4, ***p < 0.001; n.s. means no statistical difference). Collectively, these results suggest that TRPC6 protein degradation induced by glutamate is mediated by NR2B-containing NMDARs through activating calpain. In contrast, TRPC6 mRNA up-regulation induced by glutamate is likely via a mechanism independent of NR2B-containing NMDARs.
NR2A-containing NMDARs mediate TRPC6 up-regulation
We then investigated the possible role of NR2A-containing NMDARs in TRPC6 expression. As shown in Fig. 5a , no change in the production of SBDP-150/145 induced by glutamate was observed when the neurons were incubated with TCN201 (n = 3), an agent known as a specific antagonist for NR2A subunit (Bettini et al. 2010) . Thus, NR2A-containing NMDARs were not involved in calpain activation induced by glutamate. However, increase in TRPC6 protein levels induced by glutamate was greatly inhibited when neurons were incubated in the presence of TCN201 ( Fig. 5a and b ; n = 3, **p < 0.01 vs. control or vehicle). Further, TCN201 did not induce the cell death ( Fig. S2a, b ; n = 7). Next, effects of TCN201 on TRPC6 mRNA levels were assessed and the increase in TRPC6 mRNA levels induced by glutamate was greatly suppressed when the neurons were incubated in the presence of TCN201 ( Fig. 5c ; n = 4, *p < 0.05; **p < 0.01 vs. control or vehicle). Moreover, when the NR2A was down-regulated by its siRNAs ( Fig. S3a ; n = 4) the increase in both TRPC6 protein and mRNA levels induced by glutamate was greatly suppressed and production of SBDP-150/145 was not changed (Fig. 5d , e and f; n = 4, **p < 0.01; ***p < 0.001; n.s. means no statistical difference). These results suggest that NR2A-containing NMDARs are important for TRPC6 mRNA up-regulation induced by glutamate and NR2A-containing NMDARs are not involved in activation of calpain and TRPC6 degradation.
It has been reported that activated calcineurin can dephosphorylate nuclear factor of activated T-cells (NFAT) and enhance TRPC6 expression in cardiomyocytes and podocytes (Koitabashi et al. 2010; Nijenhuis et al. 2011 ). Therefore, we tested whether up-regulation of TRPC6 mRNA induced by glutamate is mediated by the calcineurin/NFAT signaling pathway. Treatment of neurons with Cyclosporin A (CsA), known as an inhibitor of calcineurin (Koitabashi et al. 2010) , markedly suppressed the enhancement of both TRPC6 protein (n = 3) and mRNA (n = 4) levels induced by glutamate (Fig. 6a, b and c; *p < 0.05; **p < 0.01 vs. control or vehicle group). No change in the production of SBDP-150/145 induced by glutamate was observed when the neurons were incubated in the presence of CsA ( Fig. 6a ; n = 3), suggesting that CsA does not alter the activity of calpain. Taken together, these results support an explanation that NR2A-containing NMDARs mediate the increase in TRPC6 transcription through the calcineurin pathway stimulated by glutamate.
Glutamate increases TRPC6 activity in cultured cortical neurons We then determined whether the TRPC6 activity was increased after the neurons incubated with glutamate by Ca 2+ imaging analysis. The OAG, a membrane-permeable diacylglycerol analog known to activate TRPC3/6 channels (Hofmann et al. 1999) , induced the [Ca 2+ ] i elevation in cultured cortical neurons (Fig. 7a and b) . The [Ca 2+ ] i elevation induced by OAG was greatly enhanced after the neurons incubated with glutamate for 4 h ( Fig. 7c and d ; n = 23-33, *p < 0.05; ***p < 0.001 vs. control or treated group) and this [Ca 2+ ] i elevation was abolished by SKF96365, an agent known to inhibit TRPC channel activities (Roshanravan and Dryer 2014). As no change in TRPC3 expression was found after glutamate treatment (Fig. 1b and d) , together, these results support an explanation that glutamate increases TRPC6 expression and hence its activities.
We next examined the TRPC6 activity in the neurons pretreated with glutamate in the presence or absence of TCN201, CsA or Ifenprodil. The TCN201 or CsA suppressed the [Ca 2+ ] i elevation compared with vehicle ( Fig. 7e and f ; n = 23-27, *p < 0.05; **p < 0.01 vs. control, vehicle or glutamate). On the contrary, Ifenprodil further enhanced [Ca 2+ ] i elevation ( Fig. 7e and f ; n = 23-27, *p < 0.05; **p < 0.01 vs. control, vehicle or glutamate). Taken together, these results suggest that TRPC6 activity is increased in cultured cortical neurons preincubated with glutamate, which can be suppressed by blocking NR2A-containing NMDARs or be enhanced by blocking NR2B-containing NMDARs.
Discussion
In this study, we show that NR2A-and NR2B-containing NMDARs exert opposite roles in TRPC6 expression. Activating NR2A-containing NMDARs induces TRPC6 transcription through calcineurin, while activating NR2B-containing NMDARs mediates TRPC6 degradation through calpain (Fig. 8) . Several lines of evidence support this conclusion. First, both TRPC6 up-regulation and degradation are induced by glutamate in the primary cultured cortical neurons. Second, TRPC6 degradation induced by glutamate is blocked by a selective antagonist of NR2B-containing NMDARs, ifenprodil, the inhibitor of calpain, calpeptin and siRNAs against NR2B. Third, enhancement in TRPC6 expression at mRNA and protein levels are inhibited by a selective antagonist of NR2A-containing NMDARs, TCN201, the inhibitor of calcineurin, CsA and siRNAs against NR2A. Fourth, the OAGinduced Ca 2+ influx was increased in the neurons pretreated with glutamate, which was sensitive to SKF96365, a nonspecific TRPC channel inhibitor. Last, TCN201 suppressed, while Ifenprodil enhanced, the OAG-induced Ca 2+ influx in the neurons pretreated with glutamate. Our results thus reveal a novel mechanism by which TRPC6 expression in the neurons is differentially regulated by glutamate. Therefore, the balance between the activation of NR2A-or NR2B-containing NMDARs will control the expression of TRPC6 in the neurons.
The mechanisms by which NR2A-and NR2B-containing NMDARs exert their opposing effects on TRPC6 expression is not entirely clear at the present. It has been reported that the NR2A and NR2B subunits are preferentially expressed at synaptic and extrasynaptic sites, respectively Tovar and Westbrook 1999) . Moreover, they are coupled with different signal pathways (Tu et al. 2010 ) and activation of synaptic or extrasynaptic NMDARs leads to opposing effects on neurons (Hardingham et al. 2002) . Therefore, one possibility is that different subcellular localization of the two subunits activated by glutamate is linked to calcineurin/ NFAT or calpain pathways, leading to TRPC6 expression or degradation, respectively. Another possibility is that the NR2A-and NR2B-containing NMDARs mediate calcium ion influx with distinct kinetics (Cull-Candy and Leszkiewicz 2004) and then activation of one or the other subunit may induce distinct increase in calcium ion level, leading to different outcomes. The third possibility is that different NR2 subpopulations exert diverse roles through coupling with different post-synaptic proteins via their C-terminal regions (Sheng and Pak 2000; Kohr et al. 2003) . It has been reported that NR1-NR2B heteromers have higher affinity than NR1-NR2A heteromers to glutamate (Laurie and Seeburg 1994; Priestley et al. 1995) . Further, recovery from desensitization was slower for NR1/NR2B than for NR1/NR2A channels after glutamate application . So, the possibility is that the different sensitivity to glutamate of NR1-NR2A and NR1-NR2B heteromers may mediate distinct post-synaptic effects and couple with different signal pathways.
One of the important implications of this study is that the homeostatic expression of TRPC6 in the neurons is well controlled by glutamate, the key excitatory neurotransmitter in the CNS. Previous studies have shown that dysregulated expression of TRPC6 is related to stroke, epilepsy and AD, and maintaining the stable expression of TRPC6 prevents neuronal injury or slows down the process of diseases (Du et al. 2010; Li et al. 2012; Wang et al. 2015; Zeng et al. 2015) . For instance, TRPC6 protein is greatly degraded by calpain during cerebral ischemia and inhibition of TRPC6 degradation ameliorates ischemic neuronal damage (Du et al. 2010; Lin et al. 2013a,b) . Similarly, NR2B-dependent activation of calpain promotes the pathogenesis of AD (Saito et al. 1993; Xu et al. 2009; Liang et al. 2010) . Furthermore, TRPC6 can interact with amyloid precursor protein to reduce Ab production (Wang et al. 2015) . Combination of these findings with those in this study, it is possible that degradation of TRPC6 induced by calpain is likely a crucial factor for the pathogenesis of AD (Lu et al. 2017) . Nevertheless, all these results support the importance of maintaining stable neuronal expression of TRPC6 in normal functions of CNS. Additionally, despite a large body of evidence has shown that activation of NR2A-and NR2B-containing NMDARs plays a major role in neural disorders, directly activating or blocking them is not appropriate because these interventions could disturb their important physiological functions, leading to certain side effects. In this context, manipulating the downstream signal pathways of NR2A or NR2B subunits to balance TRPC6 expression might provide a new strategy to intervene the pathogenesis of the diseases associated with NR2A or NR2B subunits.
In conclusion, TRPC6 expression is bidirectionally regulated by NR2A-and NR2B-containing NMDARs in neurons. The findings in this study will deepen our understanding on the regulatory mechanism of TRPC6 expression in CNS and may suggest new strategies to control certain diseases associated with its expression level.
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